<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38211604</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-1253</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The lancet. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.</ArticleTitle><Pagination><StartPage>238</StartPage><EndPage>250</EndPage><MedlinePgn>238-250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(23)00398-9</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-1253(23)00398-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Linaclotide, a guanylate cyclase C agonist, has been approved in the USA for the treatment of chronic idiopathic constipation and irritable bowel syndrome with predominant constipation in adults. We aimed to assess the efficacy and safety of linaclotide in paediatric patients aged 6-17 years with functional constipation.</AbstractText><AbstractText Label="METHODS">This randomised, double-blind, placebo-controlled, multicentre, phase 3 study was done at 64 clinic or hospital sites in seven countries (USA, Canada, Israel, Italy, the Netherlands, Ukraine, and Estonia). Patients aged 6-17 years who met modified Rome III criteria for functional constipation were randomly assigned (1:1), with a block size of four and stratified by age (6-11 years and 12-17 years), to receive either oral linaclotide 72 &#x3bc;g or placebo once daily for 12 weeks. Participants, investigators, and data assessors were masked to assignment. The primary efficacy endpoint was change from baseline (CFB) in the 12-week frequency rate of spontaneous bowel movements (SBMs; occurring in the absence of rescue medication on the calendar day of or before the bowel movement) per week and the secondary efficacy endpoint was CFB in stool consistency over the 12-week treatment period; efficacy and safety were analysed in all patients in the randomised population who received at least one dose of study intervention (modified intention-to-treat population and safety population, respectively). The study is registered with ClinicalTrials.gov, NCT04026113, and the functional constipation part of the study is complete.</AbstractText><AbstractText Label="FINDINGS">Between Oct 1, 2019, and March 21, 2022, 330 patients were enrolled and randomly assigned to linaclotide (n=166) or placebo (n=164). Two patients in the linaclotide group did not receive any treatment; thus, efficacy and safety endpoints were assessed in 328 patients (164 patients in each group). 293 (89%) patients completed the 12-week treatment period (148 in the linaclotide group and 145 in the placebo group). 181 (55%) of 328 patients were female and 147 (45%) were male. At baseline, the mean frequency rate for SBMs was 1&#xb7;28 SBMs per week (SD 0&#xb7;87) for placebo and 1&#xb7;16 SBMs per week (0&#xb7;83) for linaclotide, increasing to 2&#xb7;29 SBMs per week (1&#xb7;99) for placebo and 3&#xb7;41 SBMs per week (2&#xb7;76) for linaclotide during intervention. Compared with placebo (least-squares mean [LSM] CFB 1&#xb7;05 SBMs per week [SE 0&#xb7;19]), patients treated with linaclotide showed significant improvement in SBM frequency (LSM CFB 2&#xb7;22 SBMs per week [0&#xb7;19]; LSM CFB difference 1&#xb7;17 SBMs per week [95% CI 0&#xb7;65-1&#xb7;69]; p&lt;0&#xb7;0001). Linaclotide also significantly improved stool consistency over placebo (LSM CFB 1&#xb7;11 [SE 0&#xb7;08] vs 0&#xb7;69 [0&#xb7;08]; LSM CFB difference 0&#xb7;42 [95% CI 0&#xb7;21-0&#xb7;64]; p=0&#xb7;0001). The most reported treatment-emergent adverse event (TEAE) by patients treated with linaclotide was diarrhoea (seven [4%] of 164 vs three [2%] of 164 patients in the placebo group) and by patients treated with placebo was COVID-19 (five [3%] vs four [2%] in the linaclotide group). The most frequent treatment-related TEAE was diarrhoea (linaclotide: six [4%] patients; placebo: two [1%] patients). One serious adverse event of special interest (treatment-related severe diarrhoea resulting in dehydration and hospitalisation) occurred in a female patient aged 17 years in the linaclotide group; this case resolved without sequelae after administration of intravenous fluids. No deaths occurred during the study.</AbstractText><AbstractText Label="INTERPRETATION">Linaclotide is an efficacious and well tolerated treatment for functional constipation in paediatric patients and has subsequently been approved by the US Food and Drug Administration for this indication.</AbstractText><AbstractText Label="FUNDING">AbbVie and Ironwood Pharmaceuticals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Lorenzo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khlevner</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Vagelos College of Physicians and Surgeons and New York Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. Electronic address: jk3065@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Araujo</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Wangang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huh</LastName><ForeName>Susanna Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Ironwood Pharmaceuticals, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Masakazu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ironwood Pharmaceuticals, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyams</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Connecticut Children's Medical Center, Hartford, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nurko</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benninga</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewson</LastName><ForeName>Marcella E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>AbbVie, North Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saps</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Miller School of Medicine, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04026113</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101690683</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>N0TXR0XR5X</RegistryNumber><NameOfSubstance UI="C523483">linaclotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Gastroenterol Hepatol. 2024 Mar;9(3):191-192. doi: 10.1016/S2468-1253(23)00440-5.</RefSource><PMID Version="1">38211605</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="Y">Constipation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="Y">Peptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests CDL has received consulting fees from AbbVie, Ironwood Pharmaceuticals, Mallinckrodt, NeurAxis, QOL Medical, and Takeda. JK has received honoraria from Abbott Pediatric Nutrition and has participated on a data safety monitoring board and advisory board for AbbVie. GR-A and WX are employees of AbbVie and own stock or stock options. SYH and MA are employees of Ironwood Pharmaceuticals and own stock or stock options. JSH has received consulting fees from Takeda and Thetis and has participated on data safety monitoring boards or advisory boards for Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, and Pfizer. SN has received consulting fees from Innovative Health Solutions. MAB has received consulting fees from Allergan, Mallinckrodt, Danone, FrieslandCampina, Sensus, United Pharmaceuticals, HiPP, Coloplast, and Wellspect, and has received honoraria from Abbott and Menarini. MSi has been a clinical investigator for Moderna, Sanofi, Dermavant, Pfizer, Merck, and Incyte. MEH is employed at AbbVie. MSa has received consulting fees from AbbVie, Ironwood Pharmaceuticals, QOL Medical, IQVIA, and Takeda.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38211604</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(23)00398-9</ArticleId><ArticleId IdType="pii">S2468-1253(23)00398-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>